What Teduglutide is
Teduglutide is a GLP-2 analog used in approved intestinal-failure contexts and represents one of the clearest translational gut-peptide medicines.
Teduglutide is grouped under Approved / Clinical / Fat Loss + GLP-1s on PeptideFactCheck because it matters because it is a real peptide-drug example in gut biology, not just a research-peptide story.
The useful starting point is to separate the molecule itself from the internet story around it. It matters because it is a real peptide-drug example in gut biology, not just a research-peptide story.
Why people keep looking it up
It matters because it is a real peptide-drug example in gut biology, not just a research-peptide story.
Teduglutide is a GLP-2 analog used in approved intestinal-failure contexts and represents one of the clearest translational gut-peptide medicines.
Teduglutide tends to stay in the conversation because it touches a familiar public theme: glp-2 analog, intestinal adaptation, and gut peptide. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved gut-peptide analog with direct human evidence and labeling.
Human trials and labeling support specific approved uses.
Mechanism is aligned with GLP-2 intestinal-growth and barrier-function biology.
Why this page carries the current tier: Approved gut-peptide analog with direct human evidence and labeling.
The current seed trail for Teduglutide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Approved clinical use should be read through current labels rather than generalized into DIY gut-repair narratives.
FDA-approved teduglutide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Teduglutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Teduglutide is CID 16139605. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16139605
- Formula
- C164H252N44O55S
- Molecular weight
- 3752.1
- InChIKey
- CILIXQOJUNDIDU-ASQIGDHWSA-N
Matched synonyms include Teduglutide, Gattex, 197922-42-2, revestive, ALX-0600, Gattex Kit, Gly(2)-GLP-2, ALX 0600.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Teduglutide returns 50 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Teduglutide returns 368 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Gattex
- Generic names
- TEDUGLUTIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA203441
Indications and usage. 1 INDICATIONS AND USAGE GATTEX ® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support . GATTEX ® is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. ( 1 )
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Acceleration of Neoplastic Growth : In case of intestinal malignancy, discontinue GATTEX. The decision to continue GATTEX in patients with non-gastrointestinal malignancy should be made based on benefit risk considerations. ( 5.1 ) In adult patients, colonoscopy and upper GI endoscopy (or alternate imaging) is recommended after 1 year of treatment. Perform subsequent colonoscopies and uppe...
Contraindications. 4 CONTRAINDICATIONS None. None. ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.